Epigenetics and oncology

Pharmacotherapy

Volumn 34, Issue 5, 2014, Pages 495-505

  Mummaneni, Padmaja ^a   Shord, Stacy S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

epigenetics; oncology; targeted therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BIOLOGICAL MARKER; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; ISOTRETINOIN; ROMIDEPSIN; VORINOSTAT; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SCREENING; CARCINOGENESIS; DNA METHYLATION; DNA MODIFICATION; DRUG RESEARCH; EPIGENETICS; HISTONE MODIFICATION; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; ONCOLOGY; PREDICTIVE VALUE; REVIEW; TUMOR RESISTANCE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84899117261     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1408     Document Type: Review

References (97)

1. Vidaza (azacitidine). Available from http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/050794s024lbl.pdf. Accessed June 3, 2013.
2. Dacogen (decitabine). Available from http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/021790s006lbl.pdf. Accessed June 3, 2013.
3. Isotadax (romidepsin). Available from http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/022393s006lbl.pdf. Accessed June 3, 2013.
4. Zolinza (vorinostat). Available from http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021991s002lbl.pdf. Accessed June 3, 2013.
5. Csoka AB, Szyf M,. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses 2009; 73: 770-80.
6. Goldberg AD, Allis CD, Bernstein E,. Epigenetics: a landscape takes shape. Cell 2007; 128: 635-8. (Pubitemid 46273578)
7. Issa JP,. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-93.
8. Jones PA, Baylin SB,. The epigenomics of cancer. Cell 2007; 128: 683-92. (Pubitemid 46273572)
9. Portela A, Esteller M,. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-68.
10. Kelly TK, De Carvalho DD, Jones PA,. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28: 1069-78.
11. Lao VV, Grady WM,. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700.
12. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28. (Pubitemid 34587077)
13. Kudo Y, Keisuke T, Keisuke Y, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 2012; 103: 670-6.
14. Kraus TF, Globisch D, Wagner M, et al. Low values of 5- hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors. Int J Cancer 2012; 131: 1577-90.
15. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012; 150: 1135-46.
16. Yang H, Liu Y, Bai F, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013; 32: 663-98.
17. Jin SG, Jiang Y, Qiu R, et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 2011; 71: 7360-5.
18. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-43.
19. Pfeifer GP, Kadam S, Jin SG,. 5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin 2013; 6: 10.
20. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63.
21. Luo SY, Lam DCL,. Oncogenic driver mutations in lung cancer. Transl Respir Med 2013; 1: 6.
22. Stratton MR, Campbell PJ, Futreal PA,. The cancer genome. Nature 2009; 458: 719-24.
23. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13-27.
24. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41: 178-86.
25. Gal-Yam EN, Saito Y, Egger G, Jones PA,. Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 2008; 59: 267-80. (Pubitemid 351287937)
26. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-25.
27. van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005; 23: 3886-96. (Pubitemid 46218691)
28. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-22.
29. Glasspool RM, Teodoridis JM, Brown R,. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006; 94: 1087-92.
30. Fahy J, Jeltsch A, Arimondo PB,. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat 2012; 22: 1427-42.
31. Kalari S, Pfeifer GP,. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 2010; 70: 277-308.
32. Marks PA,. Epigenetic targeted anti-cancer drugs: an unfolding story. Oncology (Williston Park) 2011; 25: 231-5.
33. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-6. (Pubitemid 34288859)
34. O'Dwyer K, Maslak P,. Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin Pharmacother 2008; 9: 1981-6.
35. de Vos D, van Overveld W,. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 2005; 84 (suppl 1): 3-8.
36. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27: 3842-8.
37. Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009; 15: 3881-8.
38. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-85. (Pubitemid 44629609)
39. Stresemann C, Lyko F,. Modes of action of the DNA methyltransferase inhibitors azacitidine and decitabine. Int J Cancer 2008; 123: 8-13. (Pubitemid 351705186)
40. Karon M, Sieger L, Leimbrock S, et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973; 42: 359-65.
41. Momparler RL, Rivard GE, Gyger M,. Clinical trial on 5-aza- 2â€-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985; 30: 277-86. (Pubitemid 17207209)
42. Petti MC, Mandelli F, Zagonel V, et al. Pilot study of 5-aza-2â€-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993; 7 (suppl 1): 36-41. (Pubitemid 23184798)
43. Jain PK,. Epigenetics: the role of methylation in the mechanism of action of tumor suppressor genes. Ann N Y Acad Sci 2003; 983: 71-83. (Pubitemid 36399321)
44. Papi A, Ferreri AM, Rocchi P, Guerra F, Orlandi M,. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Res 2010; 30: 535-40.
45. Reichert N, Choukrallah MA, Matthias P,. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 2012; 69: 2173-87.
46. Minucci S, Pelicci PG,. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51. (Pubitemid 43054973)
47. Bolden JE, Peart MJ, Johnstone RW,. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84. (Pubitemid 44348499)
48. Bertino EM, Otterson GA,. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011; 20: 1151-8.
49. Marks PA, Dokmanovic M,. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005; 14: 1497-511. (Pubitemid 41749195)
50. Richon VM,. Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Epigenomics 2010; 2: 457-65.
51. Marks PA, Richon VM, Miller T, Kelly WK,. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-68. (Pubitemid 39140958)
52. Khan O, La Thangue NB,. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85-94.
53. Chang J, Varghese DS, Gillam MC, et al. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 2012; 106: 116-25.
54. Thurn KT, Thomas S, Moore A, Munster PN,. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011; 7: 263-83.
55. Gore SD,. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2011; 2011: 550-5.
56. Griffiths EA, Gore SD,. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008; 45: 23-30.
57. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114: 2764-73.
58. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011; 1: 598-607.
59. Turner NC, Reis-Filho JS,. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012; 13: e178-85.
60. Dannenberg JH, Berns A,. Drugging drug resistance. Cell 2010; 141: 18-20.
61. Wilting RH, Dannenberg JH,. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat 2012; 15: 21-38.
62. Wei SH, Brown R, Huang TH,. Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann N Y Acad Sci 2003; 983: 243-50. (Pubitemid 36399337)
63. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R,. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10: 4420-6. (Pubitemid 38878884)
64. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R,. Reversal of drug resistance in human tumor xenografts by 2â€-deoxy-5-azacytidine- induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039-44.
65. Strathdee G, MacKean MJ, Illand M, Brown R,. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335-41. (Pubitemid 29192710)
66. Zeller C, Dai W, Steele NL, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012; 31: 4567-76.
67. Balch C, Huang TH, Brown R, Nephew KP,. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004; 191: 1552-72. (Pubitemid 39491180)
68. Baylin SB, Jones PA,. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-34.
69. Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degrees of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000; 6: 4618-27. (Pubitemid 32110396)
70. Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998; 92: 4296-307. (Pubitemid 28544347)
71. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26: 4189-99.
72. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4.
73. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003. (Pubitemid 40349502)
74. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG,. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793-7. (Pubitemid 29086728)
75. Zhang W, Peyton M, Xie Y, et al. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol 2009; 4: 161-6.
76. Witta S,. Histone deacetylase inhibitors in non-small-cell lung cancer. J Thorac Oncol 2012; 7: S404-6.
77. Schenk T, Chen WC, Göllner S, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012; 18: 605-11.
78. Harris WJ, Huang X, Lynch JT, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012; 21: 473-87.
79. Lokken AA, Zeleznik-Le NJ,. Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell 2012; 21: 451-3.
80. Holbeck SL, Collins JM, Doroshow JH,. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 2010; 9: 1451-60.
81. Mallarkey G, Coombes RC,. Advancing breast cancer therapy by translational research: highlights of the Improving Care and Knowledge through Translational Research (IMPAKT) breast cancer conference. Ther Adv Med Oncol 2011; 3: 223-7.
82. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008; 14: 6296-301.
83. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-67. (Pubitemid 40170861)
84. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2â€- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-40. (Pubitemid 38268953)
85. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-28. (Pubitemid 34742100)
86. Issa JP, Byrd JC,. Decitabine in chronic leukemias. Semin Hematol 2005; 42: S43-9. (Pubitemid 40961872)
87. Schiff D, Brown PD, Giannini C,. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2009; 69: 1366-73. (Pubitemid 47482451)
88. Everhard S, Kaloshi G, Crinière E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006; 60: 740-3. (Pubitemid 46048490)
89. Manuyakorn A, Paulus R, Farrell J, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 2010; 28: 1358-65.
90. Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2013; 63: 88-105.
91. Brennan K, Garcia-Closas M, Orr N, et al. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res 2012; 72: 2304-13.
92. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006; 66: 3338-44.
93. Hutajulu SH, Indrasari SR, Indrawati LP, et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Mol Cancer 2011; 10: 48.
94. Van Neste L, Bigley J, Toll A, et al. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol 2012; 12: 16.
95. Maxwell A, McCudden CR, Wians F,. Recent advances in the detection of prostate cancer using epigenetic markers in commonly collected laboratory samples. Lab Med 2009; 40: 171-8.
96. An SW, Kim NK, Chung HC,. Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening. Yonsei Med J 2009; 50: 331-4.
97. Lee HS, Hwang SM, Kim TS, et al. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Transl Oncol 2013; 6: 290-6.